VERAXA is an early-stage biotechnology company with game-changing antibody discovery, screening and conjugation technology yielding the most optimized Antibody Drug Conjugates (ADCs) at scale.
We are looking for partners or collaborators to license / co-develop:
our internal pipeline of ADCs which are optimized for internalization and toxicity.
our click-chemistry technology for side-specific conjugation and the generation of ADCs with a highly precise drug-to-antibody ratio and improved PK/PD.
novel functional antibodies using our one-step microfluidic screening platform.
We are not looking to provide these services as a contract research organization, we are looking for partners to co-develop the best ADCs possible and bring them into the clinic.
With our proprietary high throughput droplet-based microfluidic platform, we can screen entire immune repertoires containing millions of antibody-secreting cells for binding, functionality, and internalization in one step, on a single-cell level. Our unique ADC technology utilizes genetic code expansion and bioorthogonal click chemistry to precisely and efficiently conjugate payloads at freely selectable antibody sites.
We are looking for partners or collaborators to license / co-develop:
our internal pipeline of ADCs which are optimized for internalization and toxicity.
our click-chemistry technology for side-specific conjugation and the generation of ADCs with a highly precise drug-to-antibody ratio and improved PK/PD.
novel functional antibodies using our one-step microfluidic screening platform.
We are not looking to provide these services as a contract research organization, we are looking for partners to co-develop the best ADCs possible and bring them into the clinic.
With our proprietary high throughput droplet-based microfluidic platform, we can screen entire immune repertoires containing millions of antibody-secreting cells for binding, functionality, and internalization in one step, on a single-cell level. Our unique ADC technology utilizes genetic code expansion and bioorthogonal click chemistry to precisely and efficiently conjugate payloads at freely selectable antibody sites.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
